Pure Global

Association Between Postoperative Administration of L-Arginine and CSA-AKI - Trial NCT06248359

Access comprehensive clinical trial information for NCT06248359 through Pure Global AI's free database. This phase not specified trial is sponsored by Xijing Hospital and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 7000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06248359
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06248359
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Association Between Postoperative Administration of L-Arginine and CSA-AKI
Association Between Early Postoperative L-Arginine Administration and Acute Kidney Injury Following Cardiac Surgery

Study Focus

Acute Kidney Injury

L-Arginine hydrochloride

Observational

drug

Sponsor & Location

Xijing Hospital

Xi'an, China

Timeline & Enrollment

N/A

Dec 01, 2023

Mar 01, 2024

7000 participants

Primary Outcome

incidence of postoperative AKI

Summary

To investigate the association between the the early administration of L-Arginine after
 CPB-assisted cardiac surgery and the incidence of CS-AKI in adult patients. To test if it can
 reduce the incidence of post-operative AKI.

ICD-10 Classifications

Injury of kidney
Acute renal failure
Acute renal failure, unspecified
Other acute renal failure
Acute renal failure with tubular necrosis

Data Source

ClinicalTrials.gov

NCT06248359

Non-Device Trial